Search research articles
Contact Us
Filters
Showing results (31-40 of 44) with videos related to
Page
of 5
Sort By:
Neurology
|
December 1, 1996
A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group
L J Thal, G Schwartz, M Sano, et al.
Journal of Clinical and Experimental Neuropsychology
|
May 15, 2007
Mayo's Older Americans Normative Studies: Visual Form Discrimination and copy trial of the Rey-Osterrieth Complex Figure
M M Machulda, R J Ivnik, G E Smith, et al.
Neurology
|
February 13, 2003
Mild cognitive impairment in the oldest old
B Boeve, J McCormick, G Smith, et al.
Neurology
|
January 28, 2004
DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging
T J Ferman, G E Smith, B F Boeve, et al.
Alzheimer Disease and Associated Disorders
|
January 1, 1997
Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study
R C Mohs, D Knopman, R C Petersen, et al.
Neurology
|
January 29, 2003
MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD
C R Jack, M Slomkowski, S Gracon, et al.
Neurology
|
September 16, 2009
Retinal microvascular abnormalities and cognitive decline: the ARIC 14-year follow-up study
S R Lesage, T H Mosley, T Y Wong, et al.
Neurology
|
April 12, 2012
Similar clinical and neuroimaging features in monozygotic twin pair with mutation in progranulin
E McDade, B F Boeve, T M Burrus, et al.
Nature Communications
|
March 29, 2022
A computational model of neurodegeneration in Alzheimer's disease
D Jones, V Lowe, J Graff-Radford, et al.
Archives of Neurology
|
July 25, 1998
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype
D Galasko, L Chang, R Motter, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 44) with videos related to
Sort By:
Page
of 5
Neurology
|
December 1, 1996
A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group
L J Thal, G Schwartz, M Sano, et al.
Journal of Clinical and Experimental Neuropsychology
|
May 15, 2007
Mayo's Older Americans Normative Studies: Visual Form Discrimination and copy trial of the Rey-Osterrieth Complex Figure
M M Machulda, R J Ivnik, G E Smith, et al.
Neurology
|
February 13, 2003
Mild cognitive impairment in the oldest old
B Boeve, J McCormick, G Smith, et al.
Neurology
|
January 28, 2004
DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging
T J Ferman, G E Smith, B F Boeve, et al.
Alzheimer Disease and Associated Disorders
|
January 1, 1997
Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study
R C Mohs, D Knopman, R C Petersen, et al.
Neurology
|
January 29, 2003
MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD
C R Jack, M Slomkowski, S Gracon, et al.
Neurology
|
September 16, 2009
Retinal microvascular abnormalities and cognitive decline: the ARIC 14-year follow-up study
S R Lesage, T H Mosley, T Y Wong, et al.
Neurology
|
April 12, 2012
Similar clinical and neuroimaging features in monozygotic twin pair with mutation in progranulin
E McDade, B F Boeve, T M Burrus, et al.
Nature Communications
|
March 29, 2022
A computational model of neurodegeneration in Alzheimer's disease
D Jones, V Lowe, J Graff-Radford, et al.
Archives of Neurology
|
July 25, 1998
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype
D Galasko, L Chang, R Motter, et al.
Page
of 5